AngioDynamics delivered strong Q3 results, highlighting growth across its MedTech portfolio. With raised guidance and increasing adoption in key areas like Mechanical Thrombectomy and NanoKnife, the ...

Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have ...

Here is how AngioDynamics (ANGO) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year. The average of price targets set by Wall Street analysts indicates a ...

H.C. Wainwright raised the firm’s price target on AngioDynamics (ANGO) to $16 from $15 and keeps a Buy rating on the shares. The company ...

AngioDynamics, Inc.’s ANGO share price has surged by 12.42%, which has investors questioning if this is right time to sell.

AngioDynamics, Inc. ANGO reported an adjusted earnings per share (EPS) of 3 cents for third-quarter fiscal 2025, narrower than the year-ago quarter’s adjusted loss per share of 16 cents and ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment ...

LATHAM, N.Y. (AP) — LATHAM, N.Y. (AP) — AngioDynamics Inc. (ANGO) on Wednesday reported a loss of $4.4 million in its fiscal third quarter. On a per-share basis, the Latham, New York-based ...

AngioDynamics (NASDAQ:ANGO) is preparing to release its quarterly earnings on Wednesday, 2025-04-02. Here's a brief overview of what investors should keep in mind before the announcement.

AngioDynamics expects full-year results to range from a loss of 34 cents per share to a loss of 31 cents per share, with revenue in the range of $285 million to $288 million.